TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02659579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Reader Organisation's Shared Reading Programme
Description: In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Reading control
Description: Parents and children will attend a weekly shared reading group at a library for 8 weeks
Study: NCT02129205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650808
Description: Dose Escalation Phase \[Part 1\] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650808
Description: Dose Expansion Phase \[Part 2\] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
Study: NCT04304781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP/QRH dimer
Description: Peptide 919288G, Lot No. 17081402, Molecular Weight 3577.0, ≥95% purity. Stored at \<20°C. Dark green, lyophilized powder in single-use amber vials.
Study: NCT04319302

Intervention type: PROCEDURE
Intervention: Isolated Vascularized Gastric Tube (IVGT) graft
Description: A conduit was created by tubularising a vascularized segment of the greater curve of the antrum of the stomach and this was used between the remaining common hepatic duct and the duodenum.
Study: NCT03599895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D printing model
Description: Combine the 3D printing technique with imaging examination ,making the 3D model of da Vinci robot assisted radical gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non 3D printing model
Description: da Vinci robot assisted radical gastrectomy
Study: NCT01553877

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pushti packet
Description: A food composed of roasted rice, roasted lentil, molasses and soybean oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice based Ready to Use Complementary Food Supplements
Description: A rice based diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chick-pea based Ready to Use Complementary Food Supplements
Description: A chick-pea based diet.
Study: NCT01530412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Patients undergo pulmonary rehabilitation for two hours twice a week for seven weeks. The first hour comprises of an individualized exercise programme and the second hour consists of an educational component. Patients are also required to undergo inspiratory muscle training five days a week for thirty minutes and exercise for an additional three days a week for thirty minutes.
Study: NCT04275297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Treatment
Description: The psychosocial intervention will consist of 8 weekly 50-minute individual visits with the assigned therapist.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: The Attention Control will reflect a similar visit pattern and duration as intervention sessions.
Study: NCT01816412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD02-LDCB Paclitaxel coated balloon catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Uncoated Balloon Angioplasty Catheter
Study: NCT02987179

Intervention type: OTHER
Intervention: Observational
Description: Collect anthropomorphic, WatchPAT, Crit-line Monitor measurements as well as sleep questionnaires and video records
Study: NCT00956267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian diathermy (LOD)
Description: Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
Study: NCT02449681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-4000 (Tarloxotinib)
Study: NCT03019471

Intervention type: GENETIC
Intervention: Isolation of tumor DNA

Intervention type: GENETIC
Intervention: Isolation of tumor DNA

Intervention type: GENETIC
Intervention: Isolation of tumor DNA

Intervention type: GENETIC
Intervention: Isolation of tumor DNA
Study: NCT01081457

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation
Description: Comparison ON vs OFF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Comparison ON vs OFF
Study: NCT02795533

Intervention type: BEHAVIORAL
Intervention: Clinical follow-up
Description: All included patients will have a clinical follow-up consisting of:~1. A medical examination~2. Quality of life questionnaires~3. Neuropsychological test~All instruments have been translated into Norwegian and validated and tested in clinical practice.
Study: NCT03760341

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adenoidectomy - cold method
Description: a surgery for adenoid removal or reduction under general anesthesia using surgical curretes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adenoidectomy - hot method
Description: a surgery for adenoid removal or reduction under general anesthesia using suction diathermy
Study: NCT04260412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medium cut-off (MCO) dialysis membrane
Description: Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fiber mixture (Plantago Psyllium 69% and Inulin 30%)
Description: Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber mixture (Plantago Psyllium 69% and Inulin 30%)
Description: Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium propionate
Description: Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium propionate
Description: Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
Study: NCT02752750

Intervention type: OTHER
Intervention: MRI
Description: MR imaging (MRI) at 3 Tesla

Intervention type: OTHER
Intervention: MRI
Description: MR imaging (MRI) at 3 Tesla
Study: NCT04870359

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-emptive increase of immunosuppressive treatments
Description: 1. Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~2. Adjustment of the 2nd agent would be as follows:~   1. For patients who receive AZA \<75mg/day; increase the dose of AZA to 75 mg/day.~  2. For patients who receive MMF \<1g/day, increase the dose of MMF to 1g/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone and/or AZA/MMF
Description: Prednisolone and/or AZA/MMF
Study: NCT00831181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 50mg/m2 weekly dosing during RT (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesorectal excision
Description: mesorectal excision
Study: NCT03418714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvinorin A
Description: Salvinorin A, blinded doses
Study: NCT04569409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-DFU
Description: Application of ALLO-ASC-DFU sheet to Diabetic Wagner grade 2 Foot Ulcer

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Sheet
Description: Application of Vehicle sheet to Diabetic Wagner grade 2 Foot Ulcer
Study: NCT00783068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]
Description: Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
Study: NCT05215132

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: 1.5T or 3T MRI scanner (Siemens Medical Systems)

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: 1.5T or 3T MRI scanner (Siemens Medical Systems)

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: 1.5T or 3T MRI scanner (Siemens Medical Systems)

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: 1.5T or 3T MRI scanner (Siemens Medical Systems)

Intervention type: DRUG
Group type: OTHER
Intervention: Gadavist 2Ml Solution for Injection
Description: Arm 1 and Arm 3 subjects will undergo this intervention (Gadavist 2Ml solution)

Intervention type: DRUG
Group type: OTHER
Intervention: Gadavist 2Ml Solution for Injection
Description: Arm 1 and Arm 3 subjects will undergo this intervention (Gadavist 2Ml solution)
Study: NCT03382145

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00523718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riluzole
Description: 50 mg PO bid, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, 1 capsule PO bid, 12 weeks
Study: NCT01277770

Intervention type: DRUG
Intervention: Steroid-Free Maintenance Immunosuppression
Description: 10 year follow-up of steroid-free maintenance immunosuppression

Intervention type: OTHER
Intervention: Infection After Kidney Transplantation
Description: A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).

Intervention type: DRUG
Intervention: Evaluation of the DGF nomogram in Thymoglobulin
Description: An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
Study: NCT04156503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palm olein vs Lard
Description: A 5-hour postprandial feeding intervention with 2-weeks washout in between. Blood samples will be collected at hour 0 (baseline) before test meal, and hour 3, 4 and 5 after consumption of test meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palm olein vs Lard
Description: A 5-hour postprandial feeding intervention with 2-weeks washout in between. Blood samples will be collected at hour 0 (baseline) before test meal, and hour 3, 4 and 5 after consumption of test meal.
Study: NCT02017041

Intervention type: DEVICE
Intervention: Medsignals
Description: MedSignals (www.medsignals.com) is a cellular communicating medication management device designed to improve adherence. It will be used to track when medication is removed from the device at dosing times and deliver audible and visual alerts at dosing times and to relay adherence data securely to patient files. Participants will use this device throughout the 5-week trial. It is a Class I device.

Intervention type: DEVICE
Intervention: smartphone app
Description: The smartphone app being evaluated in this study is designed to support effective medication management of opioid substitution patients taking buprenorphine/naloxone.
Study: NCT04697043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic therapy followed by surgery if the disease is not progressive
Description: Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The systemic therapy followed by surgery if the disease is not progressive.
Study: NCT04304820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Between 12 and 17yo (adult dose of 150mg) Between 6 and 11yo (75 mg) Between 3 and 5 yo (2.5 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Day 1 to start of h-ATG: 2mg/kg/day by mouth (All subjects) Start of h-ATG to Month 6: 3 mg/kg/dose by mouth administered every 12 hours (12yo and above) 6 mg/kg/dose by mouth administered every 12 hours (less than 12yo) Month 6 to Month 24: Dosing to be adjusted based on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Horse-Anti-thymocyte-Globulin
Description: h-ATG at a dose of 40 mg/kg/day for 4 days (intravenously for approximately 4 hours daily) Note: Omitted in patients who have achieved a complete response at the initial NIH visit after initiating oral treatment remotely
Study: NCT01109329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HMPV challenge virus
Description: Single dose of 10\^6 plaque forming units (PFU) of recombinant HMPV small hydrophobic genes (rHMPV-SHs)
Study: NCT00088907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study: NCT04070755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-101
Study: NCT02941887

Intervention type: BEHAVIORAL
Intervention: Behavior Analysis
Description: One examiner observed global behavior of patients during a dental care session, guided by a behavioral scale.
Study: NCT03930147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASV ventilation
Description: Ventilation on ASV mode

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASV ventilation
Description: Ventilation on ASV mode

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASV ventilation
Description: Ventilation on ASV mode

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASV ventilation
Description: Ventilation on ASV mode
Study: NCT01178320

Intervention type: DRUG
Intervention: Simvastatin, simvastatin plus extended-release niacin
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.

Intervention type: DRUG
Intervention: Simvastatin, simvastatin plus extended-release niacin
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
Study: NCT05406388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl patient control device
Description: Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
Study: NCT04165590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium immunotherapy
Description: The patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites.
Study: NCT02973425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take a Break as an augmentation to NRT-sampling in Motivation Phase
Description: NRT sampling experience \& Suite of mHealth motivational tools and mini-games.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NRT and mHealth assessment tool without feedback
Description: NRT and mHealth assessment tool without feedback
Study: NCT04202952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 Tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 Tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir Tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir Tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir Tablet
Description: administered orally once daily
Study: NCT03274609

Intervention type: COMBINATION_PRODUCT
Intervention: Augmented fluoroscopy
Description: Augmented fluoroscopy based virtual navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
Study: NCT01448213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate
Description: Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorometholone
Description: Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
Study: NCT02249754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: This group will receive the nutrition education package. The package is composed of: 1) education and counselling of mothers when the child is aged 6 (baseline), 9 and 12 months; 2) training community-based nutrition counsellors at baseline and 12 months and monthly home visits, 3) supervision of community-based nutrition counsellors' work every 2 months, and 4) sensitisation meetings with family members and health staff responsible for child health at baseline and repeated at 12 months. In addition, the group will continue to attend routine health education given at health facilities every month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine health education
Description: This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine health education
Description: This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
Study: NCT03503513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate
Description: Gentamicin is compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Pharmacy mails participants treatment drug. Once received, participants will do daily instillations of 30 milliliters of solution after catheterizing their bladder at night.
Study: NCT03393715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril Oral Tablet
Description: Perindopril oral tablet morning versus evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril Oral Tablet
Description: Perindopril oral tablet morning versus evening
Study: NCT00929656

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real rTMS
Description: rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: sham rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unimanual paretic UE Training
Description: UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unimanual paretic UE Training
Description: UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
Study: NCT00607880

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vascular access device placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vascular access device placement
Study: NCT04321980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: Subcutaneous injection of OP-101 in healthy volunteers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: Subcutaneous injection of OP-101 in healthy volunteers
Study: NCT01009892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Sulfate
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Sulfate
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Sulfate
Description: Tablet